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Abstract
Background: The appropriateness of lobectomy for all elderly patients is controversial. Meanwhile, sublobar
resection is associated with reduced operative risk, better preservation of pulmonary function, and a better quality
of life, constituting a potential alternative to standard lobectomy for elderly patients with early-stage non-small cell
lung cancer (NSCLC). To date, no randomized trial comparing sublobar resection and lobectomy focusing on elderly
patients has been reported. We hypothesized that for patients at least 70 years old with clinical stage T1N0M0
NSCLC, sublobar resection is non-inferior to lobectomy for 3-year disease-free survival (DFS).
Methods/design: This is a prospective, randomized, controlled multicenter non-inferiority trial with two study arms:
sublobar resection and lobectomy groups. Comprehensive geriatric assessments will be acquired for each patient. A
total of 339 subjects will be enrolled on the basis of power calculations, and participants followed up every 6 months
post-operation for 3 years. In case of relapse, survival follow-up will be continued until 5 years or death. Pulmonary
function testing will be performed at 6, 12, and 36 months post-operation. The primary outcome is 3-year DFS;
secondary endpoints include peri-operative complications and mortality, hospitalization time, post-operative ventilator
time, overall survival, 3-year recurrence rates, post-operative pulmonary function, quality of life, geriatric assessment
data, and 4-year mortality index.
Discussion: The present study is the only prospective, multicenter, randomized controlled trial comparing sublobar
resection and lobectomy for elderly patients. The therapeutic outcomes of sublobar resection will be evaluated in
comparison with lobectomy for elderly patients (≥70 years) with early-stage NSCLC.
Trial registration number: NCT02360761: 01/24/2015 (ClinicalTrials.gov)
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Background
Lung cancer is the most commonly diagnosed malig-
nancy and the most common cause of cancer death
worldwide, and non-small cell lung cancer (NSCLC)
accounts for 80–85 % of those deaths. According to
the International Agency for Research on Cancer, an
estimated 1.8 million new lung cancer cases and 1.6
million lung cancer-related deaths occurred in 2012 [1].
Lung cancer incidence increases with age. According
to the Surveillance, Epidemiology, and End Results
(SEER) database, age-adjusted incidence of NSCLC in
populations at least 65 years old was about 20 times
higher compared with that of younger groups between
2004 and 2008 [2]. As a result of population aging, the
proportion of elderly patients is also rapidly increasing.
The median age of NSCLC diagnosis rose from 64 years
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(1974–1978) to 70 in the late 20th century (1999–2003).
Forty-seven percent of NSCLC were diagnosed in pa-
tients at least 70 years, and 14 % were above age 80 [3].
In 2005–2009, about 71 % of NSCLC cases were newly
diagnosed in patients over 70 years, and more than one
third were at least 80 years [4]. Although elderly patients
have earlier-stage lung cancer at diagnosis compared
with younger patients [5, 6], they themselves are some-
how under-represented in studies of treatment for
cancer [7].
Surgery is the primary option for treating early-stage
NSCLC [8, 9]. The Lung Cancer Study Group (LCSG)
demonstrated a threefold increase of local recurrence
and a tendency toward decreased survival among pa-
tients who underwent sublobar resection, and supported
lobectomy as the standard of care for stage I NSCLC
[10]. However, the appropriateness of lobectomy for all
elderly patients is questionable, given that declined
function of organs is an independent determinant of
post-operative mortality and morbidity, and shorter
life expectancy limits the benefit from curative-intent
resection [11, 12].
First, lobectomy has been less employed in many
elderly patients facing an opportunity for surgical
treatment. Although advanced age by itself is not an
absolute contraindication to major thoracic surgery
[13] and disease-specific survival of elderly patients
can be unrelated to age [14–17], many fewer elderly
patients with stage I/II NSCLC receive standard lobec-
tomy than the young counterparts. In the US, Nugent
et al. reported a resection rate of 6 % in patients no
younger than 80 years, although one third of them
presented with early-stage disease (stage I or II);
meanwhile, one third of patients below 45 underwent
thoracic operation, and only 6 % had stage I or II dis-
ease [18]. Similarly, in Europe, Damhuis and Schutte
found resection rates of 26 % in lung cancer patients
younger than 70 years and merely 14 % in those older
than 70 years [19].
Second, advanced age is associated with a substan-
tial increase in morbidity and mortality from lobec-
tomy [12]. It was reported that, for patients at least
80 years old, major complication rate is 30 % and
that overall mortality rate (in hospital or within
30 days) was 16 % after lobectomy [20]. A retrospect-
ive study from the Mayo Clinic reported morbidity
and mortality rates of 48.0 % and 6.3 %, respectively,
for patients at least 80 years old who underwent lob-
ectomy for lung cancer [21]. Similar conclusions were
reached in a population-based analysis, where peri-
operative complication rate exceeded 50 % in elderly
patients [22].
Third, for elderly patients with early-stage NSCLC,
competing risks of dying from co-morbidities may
exceed the risk of cancer-related deaths. Evidence from
the SEER database indicated that the 5-year probability
of dying from cardiovascular diseases is significantly
higher than that of dying from cancer in patients 70 to
79 years old who survived for 7 years and those at least
80 years old who survived for 5 years after lobectomy
[23]. Limited life expectancy of the elderly restricts the
benefit from radical resection.
Lobectomy is not the only option for elderly patients
with early-stage NSCLC. Several retrospective studies
supported sublobar resection, including segmentectomy
and wedge resection, as a sound alternative for the
elderly. A retrospective study from the SEER database
analyzing 14,555 patients with NSCLC stage I/II sug-
gested that lobectomy conveys benefits only patients
younger than 71 years [24]. Similarly, at Pittsburgh
Medical Center, Kilic et al. indicated that segmentect-
omy is associated with reduced peri-operative complica-
tions (29.5 % versus 50 %) in patients over 70 years with
stage I NSCLC but that local recurrence and overall sur-
vival rates are not significantly different [25]. A retro-
spective study from Japan found that 5-year survival
after sublobar resection is significantly inferior to that
after standard lobectomy (64.0 % and 90.9 %, respect-
ively, P < 0.0001) in the younger group (median age of
68 versus 64); however, in the elderly (median age of 78
versus 77), no substantial difference was observed
(67.6 % and 74.3 %, P = 0.92) [26]. These data demon-
strated that sublobar resection might achieve equivalent
benefits compared with lobectomy for the elderly and
that the gap in long-term outcome between sublobar re-
section and lobectomy might shrink as patient age in-
creases. Additionally, sublobar resection may play a
better role in preserving the lung function [27, 28],
which is important for patients with small lung cancer,
conferring long survival, considering the possibility of
further lung resections to treat second primary lung
tumors.
In summary, sublobar resection may be an alternative
to standard lobectomy for elderly patients with early-
stage NSCLC, resulting in less operative risk, better
preservation of pulmonary function, and improved qual-
ity of life (QoL), without compromising survival. How-
ever, trials dedicated to surgical assessments are scarce
in elderly patients, who comprise a large percentage of
all patients.
This randomized trial is, to the best of our knowledge,
the first designed to compare sublobar resection and
lobectomy for elderly patients in order to address the fol-
lowing open questions: whether in patients at least
70 years old with clinical stage T1N0M0 NSCLC (1) sub-
lobar resection can achieve similar disease-free survival
(DFS) compared with lobectomy, (2) sublobar resection
can reduce post-operative mortality and morbidity, and
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The Surgical Treatment of Elderly Patients with early-
stage non-small cell lung cancer (STEPS) study was
designed as a prospective, randomized, controlled, multi-
center non-inferiority trial with two parallel study arms.
The hypothesis was that for patients 70 or over with
clinical stage T1M0M0 NSCLC, sublobar resection could
achieve non-inferior 3-year DFS.
Eligibility criteria and patient consent
All consecutive patients referred to the surgical units
will be assessed to determine eligibility, by one dedicated
team member, according to the inclusion and exclusion
criteria described below. Each patient will be introduced
to the trial by a research group member and receive an
explanation of the study protocol. Specific informed con-
sent regarding participation in the trial, randomization,
and explanation of the surgery will be obtained before
enrolment.
The study will be carried out in accordance with the
Helsinki Declaration. It was approved by the Ethics
Committee of Peking University Institutional Review
Board on 30 October 2014 prior to registration (reference
number IRB00001052-13053).
Inclusion criteria
 Age of 70 years or older
 Pre-operation criteria (contrast-enhanced computed
tomography (CT) scan)
▪ Suspected peripheral NSCLC.
▪ Clinical stage IA (i.e., T1 N0 M0: tumor
diameter of not more than 3 cm, surrounded by
visceral pleura, short axis of lymph node of less
than 1 cm or negative lymph nodes on positron
emission tomography scan)
▪ Maximum diameter of consolidation to maximum
tumor diameter ratio (consolidation/tumor ratio,
consolidation/tumor ratio) no less than 0.5 in sub-
solid lesions.
▪ Eligibility for sublobar resection with sufficient
margin.
 Intra-operative criteria
▪ Histologically confirmed invasive NSCLC (i.e.,
NSCLC other than pre-invasive adenocarcinomas
defined by the International Association for the
Study of Lung Cancer: adenocarcinoma in situ
and minimal invasive adenocarcinoma) [29].
▪ Pathological exclusion of suspected lymph node
involvement.
▪ Feasibility of sublobar resection in terms of
surgical margin requirement.
 General criteria
▪ Signed written informed consent by the patient
or his or her entrusted party.
▪ Completed 4-year mortality index [30] and com-
prehensive geriatric assessment (CGA) if
necessary.
▪ Physiology which can tolerate lobectomy
(percentage of forced expiratory volume in
1 second (FEV1%) of at least 50 % and diffusing
capacity of the lungs for carbon monoxide
(DLCO) of at least 50 % in pulmonary function
test).
Exclusion criteria
 Inability to comply with the study procedure.
 Thoracic surgery history, except for diagnostic
thoracoscopy.
 Malignant tumor history within the past 5 years,
except for the following conditions: cured skin basal
cell carcinoma, superficial bladder carcinoma, and
uterine cervix cancer in situ.
 Any active systemic diseases, including uncontrolled
hypertension; unstable angina pectoris; newly
onset of angina pectoris within the past 3 months;
congestive heart failure (class II or more of New
York Heart Association); myocardial infarction
within the last 6 months; or severe disease in need
of medication, such as arrhythmia, liver, renal, or
metabolic diseases.
 Uncontrollable infections.
 Co-existing small-cell lung cancer.
 Psychiatric diseases.
 Other circumstances deemed inappropriate for
enrollment by the researcher.
Comprehensive geriatric assessments
For patients 70 or older with suspected clinical stage I
NSCLC, baseline data—including Vulnerable Elders
Survey (VES-13) scale, 4-year survival index, and QoL
questionnaires: Functional Assessment of Cancer Therapy-
Lung Cancer (FACT-L) and Lung Cancer Symptom Scale
(LCSS)—should first be acquired. It is not necessary to
conduct further assessments if the patient has a VES-13
score of less than 3; otherwise, the patient will be regarded
as ‘high-risk population’, and a further evaluation named
‘pre-operative assessment of cancer elderly (PACE)’ will be
mandatory [31, 32]. PACE provides a description of the
general health condition of elderly cancer patients prior to
receiving surgery comprising assessment disability, instru-
mental function, depression and cognitive status (activities
of daily living, instrumental activities of daily living,
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Geriatric Depression Scale, and Mini-Mental State
Examination score), and an additional important pre-
treatment component concerning the level of fatigue
(brief fatigue inventory), performance status, concurrent
co-morbidities, and anaesthesiologist evaluation of opera-
tive risk (American Society of Anesthesiologists, or ASA).
Following baseline data acquisition, the 4-year mortality
index is required as one of the stratification factors.
Definition of endpoints and outcome measures
Primary endpoint
 DFS at 3 years, defined as the time interval from
randomization to the earliest onset of any of the
following events at 3 years: tumor recurrence,
metastasis, or death caused by any reason.
Secondary endpoints
 Peri-operative measurements
▪ Peri-operative complications and mortality. A
peri-operative complication is defined as one
occurring after surgery and before discharge or
within 30 days post-operatively. Death cases
during this period should be recorded as peri-
operative deaths.
▪ Hospitalization time, defined as the time interval
from the day of operation to discharge.
 Chest tube duration, defined as the time interval
from the day of operation to that of chest tube
removal.
 Overall survival at 3 years, defined as the time
interval from randomization to death from any
cause at 3 years.
 3-year local recurrence and metastasis rates, defined
as the rates of loco-regional recurrence and
metastasis, respectively, in 3 years from the day
of randomization.
 6-, 12-, and 36-month post-operative pulmonary
function, defined as the pulmonary function 6, 12,
and 36 months post-randomization.
 Proportion of video-assisted thoracoscopic surgery
procedure, defined as the proportion of video-
assisted thoracoscopic surgery in each group.
 QoL, defined as the QoL questionnaire survey.
 Prospective CGA and 4-year mortality index, defined
as the CGA by VES-13 scale and PACE (if necessary)
and the prognostic evaluation of the elderly by 4-year
mortality index, respectively.
Exploratory analysis
 To investigate the relationship between radiologic/
pathologic parameters of primary NSCLC and
prognosis. The consolidation component on CT is
defined as an area of increased opacification that
completely obscures the underlying vascular
markings. Ground-glass opacity is defined as an area
of a slight, homogenous increase in density that does
not obscure the underlying vascular markings.
 To accomplish the cost/benefit analysis of sublobar
resection.
 To investigate the outcomes from participants who
underwent video-assisted thoracoscopic or open
procedures.
Randomization
The patients who meet the general and pre-operative
criteria will undergo surgery, and intra-operative criteria
should be evaluated to exclude pre-invasive adenocarcin-
oma, lymph node involvement, and inadequate surgical
margin before randomization. In this procedure, all pre-
and intra-operative suspected lymph nodes are biopsied
by frozen section sampling before tumor resection to
determine whether the patient can be included and ran-
domly assigned in this trial.
The patients meeting the intra-operative criteria will
be included and randomly assigned during surgery. The
central randomization system will be used with the
dynamic minimization random program software; a ran-
dom number will be assigned to each patient, and the
medical center for the surgery will be informed. The pa-
tients will be randomly assigned into sublobar resection
or lobectomy group by a central computer and further
sub-grouped according to age (≤80 or >80 years), patho-
logical type (adenocarcinoma and other types), tumor
size (diameter of ≤2 and >2 cm), and 4-year survival
index. Once a random number is assigned to a patient,
this specific number cannot be re-assigned another one,
even if the patient fails to complete the entire study.
Intervention
Surgical approach
Sublobar resection includes two surgical procedures:
wedge resection and segmentectomy. For nodules of not
more than 2 cm, the surgeon can choose freely between
both operation types as long as surgical margin require-
ments are met. With a maximum tumor diameter of
more than 2 cm, segmentectomy should be preferred.
Segmental artery and bronchus should be divided indi-
vidually to be classified as segmentectomy. The surgical
margin should be measured on the resected sample and
is required to be no less than the lesion diameter for tu-
mors of not more than 2 cm and no less than 2 cm for
2- to 3-cm lesions. Frozen section of the surgical margin
is not mandatory. Sublobar resection should be con-
versed to lobectomy when the frozen section indicates
lymphatic metastasis or marginal involvement. Systematic
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mediastinal lymph node dissection is mandatory if no
sampling was carried out prior to randomization. A mini-
mum of three N2 lymph stations are required; nodal levels
2, 4, and 7 should be examined on the right side, and
levels 5, 6, and 7 on the left side, along with at least three
N1 lymph stations.
The standard of lymph node dissection/sampling
applies to the lobectomy arm, as does the surgical mar-
gin requirement. When the tumor locates close to a
fused fissure, the adjacent lung tissue should be extend-
edly resected. The distance from the dissection margin
to tumor edge must be evaluated in the same manner as
with sublobar resections.
Adjuvant therapy
For patients with nodal disease, adjuvant chemotherapy
is suggested. However, given the advanced age of the
study group, the decision should be made by a multi-
disciplinary team. The recommended initiation time
should be no earlier than 30 days post-operatively, so
that surgical complications are not mistaken for adverse
events of adjuvant therapy. For patients with incomplete
resection, re-resection or radiation is recommended.
Follow-up
Post-operative follow-up
Chest CT scan and QoL evaluation will be performed at
follow-up visits every 6 months after operation for
3 years. In case of relapse, survival follow-up by tele-
phone will be proceeded. The pulmonary function will
be examined at follow-up visits in 6, 12, and 36 months
after operation.
Survival follow-up
Telephone follow-up will be used to contact patients
every 3 months if recurrence occurred until 5 years or
death, to acquire subsequent medical management and
death data. The following information should be ob-
tained at each interview: survival state; death date and
cause; disease situation, including recurrence date; de-
tailed information about therapeutic strategy, including
the first- and second-line therapies, and any other subse-
quent operations.
Adverse event reporting
A data and safety monitoring committee will monitor
patient safety, and all ongoing serious adverse events will
be closely followed until stabilization. The complications
occurring after operation until discharge, or within
30 days post-operation in discharged patients, are con-
sidered post-operative complications; death during the
same period is defined as peri-operative death. Post-
operative complications are described according to the
Common Terminology Criteria for Adverse Events 4.1
published (CTCAE version 4.1) by National Cancer
Institute of the US, reported, classified, and recorded
into case report form (CRF).
Sample size
Sample size was calculated by the PASS (Power Analysis
and Sample Size) software, based on 3-year DFS of eld-
erly patients. There were no exact published data about
the DFS rate at 3 years of elderly patients with stage I
NSCLC [33, 34], and we estimated the DFS rate at
3 years for lobectomy (control group) to be approxi-
mately 75 %. DFS rate at 3 years of 60 % for sublobar re-
section is considered unacceptable. Under our current
assumption, the 15 % of non-inferiority margin on DFS
at 3 years corresponds to a hazard ratio of 1.78. The
sample-size calculation was based on log rank test. The
calculated sample size was 339 patients, and event
number of 96 was based on an estimated post-operative
3-year DFS rate of 75 %, 10 % non-compliance, 3-year
open enrolment period, 3-year follow-up period, and
one-sided type I error rate of 0.025 with 90 % statistical
power.
Recruitment and timeline
This study is planned to start in 10 medical centers
across mainland China, and 339 elderly patients with
NSCLC at early stage will be recruited. Informed con-
sent should be signed by each patient. Enrollment was
activated in December 2015 and is expected to last
3 years. All patients will be included in post-operative
and survival follow-ups for 3 years or until death. The
actual timeline might be slightly different.
Database management
A data management plan is drafted in detail before ana-
lysis implementation, according to research scheme
characteristics and CRF collection. The draft plan
includes data quality audit, electronic database establish-
ment, and acquisition method for complete and ex-
pected data. Data quality will be checked after primary
data input into the database and verification of com-
pletely consistent entries. Data consistency and logistics
should be confirmed by a combination of artificial audit
and computer program. Any doubts raised during this
period should be resolved by researchers, and the cor-
responding update and modification will be carried
out by database specialists. The assessment program
should be repeated multiple times to avoid doubts,
and all modified data and updates recorded and ar-
chived. The CRF table will be used to record all data
with blue- or black-ink ballpoint pen in clear hand-
writing. Correction fluid or tape is prohibited during
the whole process. Researchers have to ensure CRF
table authenticity.
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Statistical methods
Statistical analyses will be performed by using SPSS
(SPSS Inc., Chicago, IL, USA). Baseline data of the two
groups will be compared by Fisher’s exact and Wilcoxon
rank-sum tests as well as two samples t test. Primary
and secondary key analysis will be carried out according
to the intention-to-treat principle, and hazard ratio and
95 % confidence interval values determined. The likeli-
hood ratio will be calculated by using Cox proportional
hazards regression analysis as bilateral P value. Peri-
operative data, including measurements and procedure
types, will be analyzed at recruitment completion. Sur-
vival data will be analyzed only at trial end.
Termination criteria
The patient has the right to terminate the research and
evaluation at any time point. Exit criteria include volun-
tarily exit without sacrificing further medical treatment;
safety issues; severe violation of the designed program
by the patient; recruitment problems, such as patient
not meeting the inclusion criteria; and loss to follow-up.
Termination program
The reasons and any possible adverse events shall be in-
quired from patients who decide to terminate the study,
and the observation and evaluation shall be performed
by the researcher per se if possible. Serious or unex-
pected adverse events shall be closely followed up. The
researcher should try as much as possible to acquire pa-
tient information from the concerned individual to
complete the final evaluation, and the efforts should be
recorded as well. The evaluation and observation report
as well as the causes of exit described by patients should
be recorded as primary data. The major causes of exit
will be kept in CRF, and the subsequent procedures,
such as follow-up examination after discharge, should be
completed as much as possible.
Discussion
The development course of the surgical procedure for
NSCLC has been quite similar to that of breast cancer,
going through a revolution from extensive resection to
better organ preservation. The history of lung cancer op-
eration began with pneumonectomy, which was first per-
formed by Gramham in 1933 [35] and then regarded as
a standard procedure. Later, in the 1960s, it was demon-
strated that lobectomy could yield equivalent radical
therapeutic effects while achieving better preservation in
lung function compared with pneumonectomy. There-
after, anatomical lobectomy in combination with lymph
node dissection or sampling has become the standard
surgical approach for NSCLC [36].
Thanks to the application of CT scan, an increasing
number of asymptomatic NSCLC cases, even those with
an ‘inert’ biological behavior, are identified at an early
stage. Therefore, sublobar resection, including wedged
resection and segmentectomy, has attracted academic at-
tention. A comparative study on lobectomy and sublobar
for stage I NSCLC, conducted by the LCSG, is the only
randomized controlled trial so far and was completed
and published in 1995. Their findings suggested that
local recurrence is increased threefold in sublobar resec-
tion compared with lobectomy, and long-term survival
rate was also slightly lower in sublobar resection, al-
though there was no statistically significant difference
[10]. The study confirmed the therapeutic effect of lob-
ectomy and refuted sublobar resection; however, this
conclusion remains highly controversial because the
enrolled tumor size was considered too large for the
sublobar resection group [37].
On the other hand, as the LCSG study implied that
sublobar resection might not be suitable for all NSCLC
patients with tumor size of less than 3 cm, sublobar
resection might be more suitable for NSCLC with
smaller size or for patients with high-risk factors as a
‘compromised’ option. That is how the two mainstream
viewpoints for sublobar resection emerged and influ-
enced the subsequent studies. Accumulating retrospect-
ive studies have compared sublobar resection and
lobectomy in terms of long-term therapeutic effects
[10, 24–26, 38–61]. Their results suggested that sub-
lobar resection could achieve similar long-term outcomes
as standard lobectomy for patients with early-stage
NSCLC (diameter of not more than 2 cm) [40, 44, 45, 50–
53, 55, 59, 61]; on the other hand, lobectomy may not
convey more beneficial effects for the elderly with NSCLC
of not more than 3 cm [24, 25, 39, 43, 47, 48, 57, 62].
However, prospective randomized controlled trials to sup-
port these assumptions are scarce.
Two randomized controlled trials assessing sublobar
resection for less advanced NSCLC have been launched:
CALGB140503 [63] (US) and JCOG0802 [37] (Japan).
Both of them aim to verify the radical therapeutic effects
of sublobar resection for NSCLC with a diameter of not
more than 2 cm. Given that ‘radical effect’ is the focus
of both trials, they may not elicit high-quality supportive
evidence on the priority of sublobar resection for elderly
patients, in whom sublobar resection may match radical-
ness with compromise.
Radical surgery may not convey sufficient benefits
given the limited life expectancy of elderly patients. In
addition to concurrent diseases and declined organ func-
tion, radical surgery is very likely to increase the oper-
ation risk. Therefore, a reasonably balanced strategy
considering radical effect, operation risk, and life quality
is needed for elderly patients with NSCLC. However,
elderly patients with lung cancer are under-represented
by far, and the present study is the first prospective
Yang et al. Trials  (2016) 17:191 Page 6 of 9
randomized controlled trial on elderly patients with
NSCLC at an early stage.
Given the complexity of life expectancy and operation
risks, CGA is adopted in the present study to differenti-
ate from trials evaluating young patients, in order to
facilitate stratified randomization and analysis.
There are two parts of CGAs, the 4-year survival scale
of Lee et al. [64] and CGA, which evaluate the benefit of
operation by life expectancy and the intervention by
operation risk, respectively.
First of all, non-tumor-caused death is common in eld-
erly patients with early NSCLC, which indicates the need
for stratification. However, such relevant studies to serve
as references to the present study are rare. The 4-year
mortality in the American cohort was analyzed by Lee et
al., who also established the 4-year survival scale [64],
which is consistent with a review published in JAMA
(2012) [30]. Therefore, the 4-year survival scale estab-
lished by Lee et al. was adopted in the present study as
the standard of stratification. Patients will be classified
into four groups: low risk (score of between 0 to 5 and
4-year mortality of 4 %), moderate risk (score of between
6 and 9 and 4-year mortality of 15 %), high risk (score of
between 10 and 13 and 4-year mortality of 42 %), and
extremely high risk (score of more than 14 and 4-year
mortality of 64 %).
In the present study, the elderly patients fulfilling the
operation criteria will undergo CGA, which is a multi-
disciplinary comprehensive assessment for the elderly,
including assessments of organ function, concurrent dis-
eases, cognitive function, psychological state, social and
economic issues, syndromes, medications, and nutri-
tional status. Recent studies showed that CGA could
predict death and complication risks [65]. Although the
CGA procedure is complex, its feasibility has been
proven by the CALGB 360401 clinical trial [66].
Based on CGA, the PACE scale proposed by Audisio
et al. in 2003 was particularly designed for elderly
patients with tumor undergoing operation [67]. The
PACE scale is a reinforced CGA and includes CGA, brief
fatigue inventory, performance status, instrumental ac-
tivities of daily living, activities of daily living, and the
ASA scale. The PACE scale has a predictive value in eld-
erly patients undergoing surgical operation, as demon-
strated by multiple-center clinical validation [68].
Given the complexity of the CGA procedure, our lack
of experience in geriatric assessments, and lack of
practice on standardized and large-scale trials, the par-
ticipants of the present study will be screened first by
the VES-13 scale before CGA. VES-13 is a self-checklist,
including age and 12 items of self-assessment concern-
ing health and organ function. Compared with conven-
tional CGA, VES-13 is more convenient and is capable
of predicting the vulnerability of elderly patients and can
be used as a pre-screening tool for CGA [31, 32]. In the
present study, patients with a score of at least 3 will be
considered high-risk subjects and followed up with
PACE evaluation.
The present study is so far the only prospective, multi-
center, randomized controlled trial comparing sublobar
resection and lobectomy for elderly patients that aims to
identify the most appropriate surgical approach for
NSCLC at an early stage, to find the balance between
radical effect and operation risk, and to assess survival
period and life quality.
If the proposed study hypothesis is verified in the
current trial, sublobar resection will be demonstrated to
achieve equivalent therapeutic outcomes compared with
lobectomy for elderly patients (≥70 years) with NSCLC
at an early stage, with respect to DFS time, hospital
stay, intubation time, peri-operative complication,
death rate, overall survival rate, recurrence and me-
tastasis rates within post-operative 3 and 5 years, and
pulmonary function 6, 12, and 36 months after oper-
ation, respectively.
Current status
The trial has received ethics approval, and enrollment
in the trial has begun but has not yet reached full
enrollment.
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